Ann: Presentation to Investors, page-15

Sadly nothing really new. However, it is further “marketing” which I guess needs to be done. It is a difficult thing to sell the intricate details of what BIT drugs do because the results are not obvious even if statistically significant. A lot more work needs to be done in the US FDA systems and for that they need a partner with big pockets. This is about convincing more investors to keep backing this endeavour. I expect the options will get over the line because there is still a little leeway in the price for that to happen. We will see. Only just over a month. Maybe they will have something lined up by then, though it doesn’t look like it at the moment.